IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why

investors.com/news/technology/travere-therapeutics-filspari-fsgs-advisory-committee-meeting

Travere Therapeutics plummeted Friday after the FDA accepted its review application for a rare kidney disease drug — with one caveat.
The post IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-05-16 13:06:35.
The Entire Business World on a Single Page. Free to Use →